#115 - David Watkins, Ph.D.: A masterclass in immunology, monoclonal antibodies, and vaccine strategies for COVID-19
David Watkins, Professor of Pathology at George Washington University, discusses immunology 101, the innate and adaptive immune systems, and how HIV and Zika research informs SARS-CoV-2 strategies. He highlights the potential of monoclonal antibodies for COVID-19 prevention and treatment.
Deep Dive Analysis
13 Topic Outline
Introduction to David Watkins and his Research Background
The Evolution of the Immune System
Immunology 101: Innate vs. Adaptive Immune Systems
B Cells, Antibodies, and Neutralizing Antibodies
Variability in Neutralizing Antibody Response to Coronavirus
Lessons from Yellow Fever Vaccine Efficacy
T Cells: The Cellular Arm of the Adaptive Immune System
Challenges of HIV and Hepatitis C: Vaccine Development vs. Treatment
Comparing SARS-CoV-2 to Other Pandemics and Viruses
Monoclonal Antibodies: A Promising Strategy for COVID-19
Different Approaches to COVID-19 Vaccine Development
Insights from Zika Virus Research Applied to SARS-CoV-2
Why a COVID-19 Vaccine Doesn't Need to Be Perfect
9 Key Concepts
Innate Immune Response
This is the initial, non-specific immune response triggered when a virus enters a cell and begins replicating. It involves cellular sensors that activate interferons, which in turn initiate the broader immune system, including the adaptive response.
Adaptive Immune Response
This advanced immune system arm, consisting of T cells and B cells, provides greater memory and specificity to pathogens. It is the fundamental basis for vaccination, allowing the body to remember and respond more effectively to future infections.
Antigen
An antigen is simply a piece of a virus or other foreign substance that the immune system recognizes as 'not self.' This recognition stimulates B cells to begin replicating and developing specific antibodies against it.
Neutralizing Antibodies
These are specific antibodies that bind to a critical part of a virus, such as the spike protein, and directly prevent it from infecting human cells. Unlike other antibodies that may bind but not block infection, neutralizing antibodies are key for protection.
Affinity Maturation
This is a beautiful evolutionary process occurring in lymph nodes where B cells, after initial weak binding to an antigen, undergo rapid replication and mutation of their surface receptors. This iterative process selects for B cells that produce antibodies with progressively higher binding affinity to the antigen.
Plasma Cells
These are large, specialized B cells that reside primarily in the bone marrow after affinity maturation. They act as 'antibody factories,' continuously producing and secreting large quantities of highly specific antibodies, including neutralizing ones, to provide long-term protection.
Cytotoxic T Cell (CD8 T cell)
Often called 'killer T cells,' these powerful immune cells recognize and destroy virus-infected cells. They identify fragments of viral proteins presented on the surface of infected cells, effectively shutting down 'virus factories' before they can release more progeny virus.
Attenuated Virus (Vaccine)
This type of vaccine uses a weakened version of a live virus that can still replicate in the body but causes mild or no disease. It elicits a robust immune response, including T and B cells, but carries a small risk for some individuals, as seen with the yellow fever vaccine.
Broadly Neutralizing Antibodies
These are rare and highly effective antibodies that can neutralize not only the specific viral strain they were generated against but also many other different strains of the same virus. They achieve this by binding to conserved regions of the virus that are essential for its function and less prone to mutation.
7 Questions Answered
The advent of the adaptive immune response, involving T and B cells, was the biggest change because it allowed for greater memory and specific responses to pathogens, forming the basis for vaccination.
IgM antibodies are typically the first to appear during a new infection, indicating a very recent exposure, and they tend to tail off over time. IgG antibodies appear later and are generally responsible for long-term immunity, containing the neutralizing antibodies.
No, common serology tests for IgG or IgM only measure the quantity of antibody bound to a piece of the virus, not whether those antibodies can actually neutralize the virus and prevent infection. A significant percentage of people may have antibodies but lack neutralizing ones.
CD8 T cells recognize and kill cells that have already been infected by a virus. They identify fragments of viral proteins presented on the surface of infected cells, then bind to and destroy these 'virus factories' before they can release more virus particles.
HIV presents unique challenges due to its enormous variability, chronic nature, and the difficulty in generating neutralizing antibodies against its sugar-shielded envelope. The virus constantly mutates and escapes immune responses, making a universal vaccine elusive.
Monoclonal antibodies offer a promising strategy for both preventing and treating COVID-19 by providing immediate, pre-made neutralizing antibodies. These can be engineered to last for several months and could protect high-risk populations or treat already infected individuals.
A COVID-19 vaccine doesn't necessarily need to provide sterilizing immunity (complete prevention of infection). Its effectiveness would be measured by its ability to significantly reduce viral load, prevent severe symptoms, decrease hospitalizations, and lower transmission rates.
9 Actionable Insights
1. Adopt Multi-faceted Viral Defense
When confronting a viral epidemic, implement a comprehensive strategy that integrates multiple interventions, including social distancing, drug treatments, and vaccines, as this combined approach is essential for effective control.
2. Explore Monoclonal Antibody Therapy
Consider monoclonal antibodies as a highly promising strategy for both preventing and treating viral infections, especially for high-risk individuals or those with suboptimal vaccine responses, as they can provide direct, temporary immunity for 3-6 months.
3. Set Realistic Vaccine Expectations
Understand that a successful vaccine for viruses like coronavirus may not achieve “sterilizing immunity” but can still be highly effective by significantly reducing viral load, preventing severe illness, and shortening the duration of infectiousness.
4. Interpret Antibody Tests Cautiously
Be aware that standard antibody tests (IgG/IgM) do not differentiate between neutralizing and non-neutralizing antibodies, meaning a positive result does not guarantee protective immunity against infection.
5. Boost Elderly Vaccine Response
Recognize that elderly individuals may not generate robust immune responses from traditional vaccines; therefore, consider monoclonal antibodies as a supplementary or alternative strategy to enhance their protection against viruses.
6. Practice Humility with New Viruses
Approach the understanding and prediction of new viruses with humility, acknowledging that initial assumptions can be incorrect and that many unknown factors influence a pathogen’s behavior and impact.
7. Learn From Past Epidemics
Apply lessons and strategies from previous viral epidemics, such as HIV, to inform and improve current responses to new threats like coronavirus, as historical challenges offer valuable guidance.
8. Prepare for Future Pandemics
Proactively anticipate and prepare for future viral pandemics, drawing insights from current experiences and past outbreaks, rather than solely reacting to crises as they emerge.
9. Value Human Clinical Data
When evaluating the efficacy and safety of health interventions, especially vaccines, prioritize human clinical trial data above animal model data, as human responses are the ultimate and most reliable determinant.
5 Key Quotes
I used to think that the most important cell in the body was the cytotoxic T cell. And worse than that, I used to think that the heart had one function and that is to pump T cells around.
David Watkins
I'll admit something kind of embarrassing. I did not know that until I met you and Stanley Perlman.
Peter Attia
Science is truly wonderful.
Peter Attia
This is not the first SARS virus we've seen in the last 20 years. So need to try to anticipate the next one. And I think that monoclonal antibodies, for me, are the way forward to treat almost all infectious disease, to prevent and treat.
David Watkins
Human data trumps everything.
Vaccinologist (quoted by David Watkins)